ABIONYX Pharma

ABNX

FR0012616852

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 09:05:08 12/06/2024 pm IST			5-day change	1st Jan Change
1.274 ^EUR	+0.16%		+2.08%	-1.09%

14/03	Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	CF
11/03	Abionyx: reduced net loss in 2023	CF

Cerenis Therapeteutics Holding will Change its Name to ABIONYX Pharma SA

September 16, 2019 at 09:30 am IST

Effective September 16, 2019, Cerenis Therapeteutics Holding will change its name to ABIONYX Pharma SA.

Latest news about ABIONYX Pharma

Abionyx Pharma: to benefit from a 1ME grant from Bpifrance	14/03	CF
Abionyx: reduced net loss in 2023	11/03	CF
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023	11/03	CI
Abionyx: CSL Behring fails in heart disease trial	16/02	CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112	15/02	CI
Abionyx: former AbbVie executive appointed CMO	09/01	CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D	08/01	CI
Abionyx: Successful completion of third GMP batch of CER-001	19/12	CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023.	07/12	CI
Abionyx: encouraging results in brain fog	24/11	CF
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023	24/11	CI
Abionyx: promising new results in uveitis	21/11	CF
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I	21/11	CI
Abionyx: cash position reaches 1.7 million euros	17/11	CF
Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology 2023 Annual Meeting "Kidney Week"	02/11	CI
Abionyx: presentation planned at ASN congress	16/23/16	CF
ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"	16/23/16	CI
Abionyx Pharma: Cyrille Tupin below 5% of capital and voting rights	11/23/11	CF
Abionyx Pharma: capital increase completed	06/23/06	CF
Abionyx Pharma Raises EUR3 Million from Share Issue	06/23/06	MT
ABIONYX Pharma SA Reports Earnings Results for the Half Year Ended June 30, 2023	26/23/26	CI
Abionyx: cash position of 1.9 million euros at the end of June	18/23/18	CF
ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess	26/23/26	CI
Abionyx: appointment of a chief digital & innovation officer	13/23/13	CF
Abionyx Pharma Names Digital, Innovation Chief	13/23/13	MT

ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2023, the company boasted a portfolio of 3 products in clinical development.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q2 2024 Sales and Revenue Release

More about the company

Income Statement Evolution

More financial data

Ratings for ABIONYX Pharma

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.274 EUR

Average target price

10.5 EUR

Spread / Average Target

+724.18%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABIONYX PHARMA	-1.09%	4.39Cr
VERTEX PHARMACEUTICALS INCORPORATED	+16.93%	12TCr
REGENERON PHARMACEUTICALS, INC.	+17.01%	11TCr
BIONTECH SE	-7.23%	2.38TCr
ARGENX SE	+1.98%	2.24TCr
GENMAB A/S	-14.29%	1.75TCr
BEIGENE, LTD.	-6.79%	1.66TCr
WUXI APPTEC CO., LTD.	-37.63%	1.64TCr
NEUROCRINE BIOSCIENCES, INC.	+2.17%	1.34TCr
SAREPTA THERAPEUTICS, INC.	+24.42%	1.15TCr

Bio Therapeutic Drugs

ABIONYX Pharma

Equities

ABNX

FR0012616852

Biotechnology & Medical Research

Cerenis Therapeteutics Holding will Change its Name to ABIONYX Pharma SA

Latest news about ABIONYX Pharma

Chart ABIONYX Pharma

Company Profile

Income Statement Evolution

Ratings for ABIONYX Pharma

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs